Latest studies
- Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK-3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007).
This study is looking at a new treatment for a type of skin cancer called cutaneous squamous cell carcinoma (cSCC). It combines a new vaccine (mRNA-4157) with an existing drug (pembrolizumab) to see if it works better than standard care for people whose cancer can be removed by surgery.
Norway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma
This study is for adults in the UK with a type of cancer called follicular lymphoma that has come back or not responded to previous treatments. It investigates a new cell therapy called tisagenlecleucel to see how well it works and if it's safe.
Adult patients with refractory or relapsed follicular lymphomaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
This study is testing a new medicine called semaglutide for people with early Alzheimer's disease. Researchers want to see if it can help improve memory and thinking, and how safe it is to use.
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s typeNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age with Achondroplasia: PROPEL 3
This study is testing a new medicine, Infigratinib, for children aged 3 to under 18 with achondroplasia. It aims to see if the medicine helps children grow taller and improves other health aspects, compared to a dummy pill.
AchondroplasiaNorway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery
This study is testing a new experimental drug, CC-90010, alongside standard treatments for a type of brain cancer called glioblastoma. It's for adults whose brain tumour has been recently diagnosed and surgically removed, either fully or in part, to see if the new drug can help.
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resectionNorway - RecruitingPHASE3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This study offers ongoing treatment with pelacarsen for people who have finished a previous trial for heart disease. It aims to check the long-term safety of the medicine, which helps lower a type of cholesterol called Lp(a).
Cardiovascular Disease and Lipoprotein(a)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has specific genetic changes (MSI-H or dMMR). It compares them to standard chemotherapy to see which is better at stopping the cancer from growing.
Microsatellite Instability High (MSI-H) or Mismatch Repair DeficientMetastatic Colorectal Cancer (dMMR)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Telangiectasia.
This study is looking for children and adults with Ataxia-Telangiectasia (A-T) to see if a new treatment called EryDex can help with their symptoms. It compares EryDex to a dummy treatment (placebo) to find out if it's effective and safe.
Ataxia TelangiectasiaNorway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)
This study is testing a new medicine called TEV-48574 for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, comparing it to a dummy medicine.
Crohn’s disease, Ulcerative colitisNorway - RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
Multiple MyelomaNorway - Active not recruitingPHASE2, PHASE3
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
This study looks at new ways to treat medulloblastoma, a type of brain tumour, in children and young people. It aims to find the best treatments based on the tumour's specific characteristics, hoping to improve the chances of recovery with fewer side effects.
Brain TumorsNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)
This study is testing a new treatment combination for locally advanced cervical cancer. It compares standard chemotherapy and radiation with the same treatment plus a new drug, pembrolizumab (Keytruda), to see if it helps patients live longer and stops the cancer from growing.
Locally Advanced Cervical CancerNorway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia
This study is looking at a new medicine called HMPL-523 for adults with a blood condition called immune thrombocytopenia (ITP). It will check if the medicine is safe, how it works in the body, and if it helps people with ITP.
Primary immune thrombocytopenia (ITP)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 (depemokimab) compared with mepolizumab or benralizumab
This study looks at a new medicine called depemokimab for severe asthma with high eosinophils. It compares it to existing treatments like mepolizumab and benralizumab over a year to see if it's just as good at preventing asthma attacks and improving control.
Severe asthma with an eosinophilic phenotypeNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaNorway - Recruiting
Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach
This study looks at how a medicine called Carglumic Acid helps people with rare conditions called Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA) over a long time. It gathers information from patient records and talks to patients and their families.
Methylmalonic AcidemiaPropionic AcidemiaNorway - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Norway - Recruiting
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
This study looks at how well a drug called VITRAKVI works and how safe it is for people with TRK fusion cancer. This type of cancer happens when certain genes fuse together. Doctors want to see how VITRAKVI helps patients in real-world use.
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionNorway - RecruitingPHASE1, PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study is for children and young adults aged 1-21 with specific types of aggressive blood cancers that have come back or not responded to treatment. It tests new drug combinations to see if they're safe and work well for those with certain genetic changes in their cancer.
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RefractoryNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
INCMGA 0012-303: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
This study is testing a new medicine, retifanlimab, alongside standard chemotherapy for anal canal cancer that has spread or come back. Researchers want to see if this new combination helps patients live longer without their cancer getting worse, compared to chemotherapy alone.
Squamous Carcinoma of the Anal CanalNorway - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MiBlock - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic migraine
This study, called MiBlock, is looking into a new way to treat chronic migraine using an injection near a nerve in the face. It aims to see if this treatment can reduce the number of headache days compared to a dummy treatment, for people whose migraines haven't responded to other treatments.
Chronic migraineNorway - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
Giant cell arteritis (GCA)Norway - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaNorway - RecruitingPHASE4
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
This study looks into why some breast cancers stop responding to treatment. We will examine tissue and blood samples from patients with specific types of breast cancer to understand how the cancer becomes resistant and find new ways to help them.
Breast CancerNorway - RecruitingPHASE3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
This study looks at a new way to treat a specific type of leukaemia (AML) with a gene change called IDH1. It adds a drug called venetoclax to standard treatment (ivosidenib and azacitidine) to see if it works better. It's for patients who can't have strong chemotherapy.
Acute Myeloid LeukemiaNorway - RecruitingPhase III
A long-term extension (LTE) study of guselkumab in pediatric participants
This study looks at the long-term safety of a medicine called guselkumab for children and young people aged 2-17 with Crohn's disease, ulcerative colitis, or a type of arthritis called juvenile psoriatic arthritis. It's for those who have already benefited from guselkumab in a previous study.
Moderately to severely active ulcerative colitis (UC), moderately to severely active Crohn's disease (CD), Juvenile psoriatic arthritis (jPsA)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)
This study is looking into a new treatment called itepekimab for people with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It will compare the new drug to a dummy treatment to see if it helps reduce flare-ups of COPD and improves lung function in former smokers.
Chronic Obstructive Pulmonary DiseaseNorway - AuthorisedTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
This study looks at a new drug, INCA33890, alongside standard treatments for advanced bowel cancer that has spread. It aims to see if adding INCA33890 helps people live longer and keeps the cancer from growing for a longer time.
Metastatic Microsatellite Stable Colorectal CancerNorway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough
This study looks at a new medicine called BI 1839100. It's for people with lung conditions like Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) who have a troublesome cough. We want to see if the medicine can reduce coughing and if it's safe to use.
Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)Norway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Batoclimab, for adults with a condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if this medicine can stop CIDP symptoms from getting worse, compared to a dummy medicine. It's an important step to find better treatments.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Norway - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
Multiple MyelomaNorway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety and tolerability of different doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF).
This study is testing a new medicine, BI 1819479, for idiopathic pulmonary fibrosis (IPF). We want to see if it can slow down the lung scarring and if it's safe. Some people will get the medicine, others a dummy pill. We'll check how your breathing changes over about a year.
idiopathic pulmonary fibrosisNorway - Active not recruitingPHASE3
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
This study compares new drug combinations (dostarlimab and niraparib) with standard care for women newly diagnosed with advanced ovarian cancer. It aims to see if these new treatments can stop the cancer from growing for longer.
Ovarian NeoplasmsOvarian, Fallopian Tube and Primary Peritoneal CarcinomaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is testing a new medicine, BI 1015550, for people with progressive fibrosing interstitial lung diseases (PF-ILDs). Researchers want to see if it helps improve lung function and is safe to use over about a year.
Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Norway - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesNorway - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A phase 1/2a study to evaluate the dose, safety, tolerability, and efficacy of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis from colorectal carcinoma following hyperthermic intraperitoneal chemotherapy
This study is looking at a new treatment for bowel cancer that has spread to the lining of the tummy. It's an early-stage trial checking if the treatment is safe, how much to give, and if it helps after a type of surgery and chemotherapy.
Peritoneal carcinomatosis (PC) from colorectal carcinomaNorway - Recruiting
Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)
This study, SENSE-II/AROUSE, is collecting information from adult patients across Europe who are being treated for a severe and prolonged seizure called Status Epilepticus. Researchers want to understand more about these seizures, how they are treated, and what factors might predict how a patient will recover.
Status EpilepticusNorway - AuthorisedTherapeutic confirmatory (Phase III)
A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signaling pathway
This study looks at whether a daily aspirin-like tablet helps people with certain types of bowel cancer (colon or rectal cancer) that have specific gene changes. It compares the tablet to a dummy pill to see if it stops the cancer from coming back.
Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTENNorway - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND567. An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
This study is looking at a new medicine called KAND567, given alongside standard carboplatin chemotherapy, for women with ovarian, fallopian tube, or primary peritoneal cancer that has come back. It aims to see how safe it is and find the best dose.
Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.Norway - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
Plasma Cell MyelomaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
This study compares a new cell therapy (Tisagenlecleucel) with standard treatments for adults with an aggressive type of lymphoma that has come back or not responded to previous therapy. Researchers want to see which treatment is better at stopping the cancer from growing.
Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
This study is looking at a new medicine called Calquence for people with chronic lymphocytic leukemia. Researchers want to see how safe the medicine is by tracking any side effects. They will also check if it helps people get better.
Chronic lymphocytic leukemiaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
This study is looking into a new medication called NUC01 for a liver condition called primary sclerosing cholangitis (PSC). It compares NUC01 with a dummy medicine (placebo) to see if it can improve liver health and stop the condition from getting worse.
primary sclerosing cholangitis (PSC)Norway - RecruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
Non-Small Cell Lung CancerNorway - Active not recruitingPHASE3
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
This study is testing a new drug, AZD9833, for advanced breast cancer. It's for people whose cancer has a specific gene change (ESR1 mutation) and are already on certain treatments. Researchers want to see if adding AZD9833 works better than current medicines.
ER-Positive HER2-Negative Breast CancerNorway - Ongoing, recruitingTherapeutic exploratory (Phase II)
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial
This study looks at new, personalised treatments for older people with certain blood cancers like Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS). It compares these 'precision' treatments with standard care to see which works best and offers the best value for money in improving quality of life.
Chronic myelomonocyte leukemia, Myelodysplastic syndrome, Acute myeloid leukemiaNorway - Active not recruitingPHASE2
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
This study is testing a new medicine, bezuclastinib, for people with certain types of mastocytosis (a rare blood disorder). It compares bezuclastinib with a dummy pill (placebo) to see if it safely helps reduce symptoms that aren't well controlled by current treatments.
SSMMastocytosis, IndolentMastocytosis, SystemicMastocytosisNorway - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisNorway